Organization · Private Equity
Endo Investors
Endo Investors is a private equity firm based in Southern Florida, focusing on early-stage life sciences companies that address chronic diseases, particularly diabetes. Founded in 2013, it aims to improve patient outcomes through innovative solutions.
Overview
What Endo Investors does
What Endo Investors is
Endo Investors is a private equity firm based in Southern Florida, focusing on early-stage life sciences companies that address chronic diseases, particularly diabetes. Founded in 2013, it aims to improve patient outcomes through innovative solutions.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Private Equity
- Founded
- Founded in 2013
- Approximate age
- About 13 years
- Structured capabilities
- Funder
- Last reviewed
- March 4, 2026
Official channels
Find Endo Investors elsewhere
Open the official website or a supported primary organization account.
Capability profile
Endo Investors as a funder
Investment thesis
Endo Investors specializes in investing in early-stage life sciences companies developing innovative solutions for chronic diseases. The organization aims to improve patient outcomes while delivering strong returns for investors.
Focus narrative
Endo Investors specializes in investing in early-stage life sciences companies that are developing innovative solutions for chronic diseases. The organization targets sectors related to diabetes and other major health issues, with a focus on improving patient outcomes and delivering strong returns for investors.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+
- Regions
- North America
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 9
- Recorded notable exits
- Capillary Biomedical and Locemia Solutions
Portfolio context
Notable portfolio companies include: Bigfoot Biomedical: Focuses on optimized insulin delivery solutions. Biolinq: Develops technology for sensing and analyzing glucose levels. Capillary Biomedical: Aims to simplify insulin infusions with its SteadiSet™ infusion set, acquired by Tandem Diabetes Care in July 2022. Cecelia Health: Combines clinical coaching and technology to assist individuals and organizations in achieving health goals. Diasome: Works on hepatocyte directed vesicle (HDV) technology to enhance insulin safety and efficacy. ILiAD Biotechnologies: A clinical-stage company focused on preventing and treating diseases caused by Bordetella Pertussis. Locemia Solutions: Developed Baqsimi, a needle-free glucagon rescue treatment for severe hypoglycemia, sold to Eli Lilly in 2015. Mellitus Health: Offers Insulin Insights™ software for precision insulin dosing recommendations. Illuminare Biotechnology: A preclinical stage company focused on intra-operative nerve visualization to reduce nerve damage risk.
Common questions
What to know about Endo Investors
Upseed classifies Endo Investors under the Private Equity organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 4, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.